LR-HEALTH-&-BEAUTY
18.6.2020 17:49:09 CEST | Business Wire | Press release
Today, the LR LIFETAKT NIGHT MASTER product was awarded the German Brand Award 2020. This is a sensational success for the LR Health & Beauty company, which launched a new segment in its health portfolio with this sleep drink.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200618005674/en/
In the “Excellent Brands” competition, the vegan, holistically designed product impressed the jury in the “Health & Pharmaceuticals” category as one of the best product brands in the industry. The nightcap also received a “Special Mention” in the cross-industry category “Product Brand of the Year”, in which the jury awards a prize for special aspects of brand management. The German Brand Institute already distinguished LR as a winner in 2019 in the “Beauty & Care” category for its 5in1 Beauty Elixir product.
“The second award in a row for an advanced product development makes me and makes us all, incredibly proud and happy, and highlights our expertise in the health field,” says Andreas Friesch, CEO of LR Health & Beauty. “True to the company motto ‘More quality for your life’, we have developed a natural, effective, non-addictive product that is in touch with today’s trends*. Receiving recognition for this motivates us to keep developing innovative product solutions in the future,” Friesch says.
The secret of healthy sleep: LR LIFETAKT NIGHT MASTER
Healthy sleep improves quality of life, strengthens the immune system and heightens performance. Sleep is a desperate challenge for many but it does not have to be.*
The NIGHT MASTER sleep drink from LR LIFETAKT is an effective dietary supplement that ensures a restful sleep over the long term, in a healthy way that is non-addictive. Natural and scientifically proven active ingredients like hops and saffron extract, aloe vera, the amino acid L-tryptophan, magnesium and zinc, as well as a vitamin B complex distinguish the highly bioavailable formula. With its threefold effect, the product promotes relaxation when falling asleep and relaxation while sleeping through the night, as well as optimized regeneration. The product is vegan and it is gluten, lactose and sugar free. www.LRNightMaster.com
German Brand Award | German Design Council
The German Brand Award is a competition presented by the German Brand Institute. The Institute was founded by the German Design Council (Rat für Formgebung) in order to strengthen brand management as a crucial factor for success in companies in the national and international competitive field. It is a driving force of German brand economy, bringing together major brand-builders and stimulating brand dialog. The German Brand Award presented by the Institute is one of the most notable German brand awards.
The German Design Council is an independent and internationally active institution that supports companies in efficiently communicating design and brand competence, while at the same time aiming to strengthen design awareness among the general public. More information at: german-brand-award.com
LR Health & Beauty
Under the motto “More quality for your life”, the LR Group of Companies, with headquarters in the German city of Ahlen, markets diverse beauty and health products in 28 different countries. These include skin care and color cosmetics, dietary supplements and fragrances. LR Health & Beauty has made it its goal to improve the well-being and health of people through its product portfolio. That is why the company keeps developing new products – from the forces of nature combined with the latest scientific discoveries. Aloe Vera has been one of LR's key competences for over 18 years, where we only use the precious leaf fillet is used. With approximately 1,200 employees and thousands of registered sales partners and customers, LR is one of the leading direct sales companies in Europe. The company has been assisting children in need and their families in various countries around the world through the LR Global Kids Fund e.V. – in a fast and non-bureaucratic way in cooperation with local established institutions.
*78% of Germans suffer from sleep problems, according to a nationwide CATI-representative survey conducted by Mente>factum on behalf of LR in 2019
View source version on businesswire.com: https://www.businesswire.com/news/home/20200618005674/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom